SCY-247, a second-generation triterpenoid antifungal, shows low risk for clinically meaningful interactions with CYP3A4 substrates: results from a phase 1 midazolam drug-drug interaction study
- DOI
- 10.1128/aac.00961-26
- Published
- 2026-11-09
- Container
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1128/aac.00961-26,
title = {SCY-247, a second-generation triterpenoid antifungal, shows low risk for clinically meaningful interactions with CYP3A4 substrates: results from a phase 1 midazolam drug-drug interaction study},
author = {Stephen Wring and Christopher Argent and Gail Murphy and David Angulo and Michelle Middle},
year = {2026},
journal = {Antimicrobial Agents and Chemotherapy},
doi = {10.1128/aac.00961-26},
url = {https://doi.org/10.1128/aac.00961-26}
}RIS
TY - JOUR TI - SCY-247, a second-generation triterpenoid antifungal, shows low risk for clinically meaningful interactions with CYP3A4 substrates: results from a phase 1 midazolam drug-drug interaction study AU - Stephen Wring AU - Christopher Argent AU - Gail Murphy AU - David Angulo AU - Michelle Middle PY - 2026 JO - Antimicrobial Agents and Chemotherapy DO - 10.1128/aac.00961-26 UR - https://doi.org/10.1128/aac.00961-26 ER -
APA
Wring, S., Argent, C., Murphy, G., Angulo, D., & Middle, M. (2026). SCY-247, a second-generation triterpenoid antifungal, shows low risk for clinically meaningful interactions with CYP3A4 substrates: results from a phase 1 midazolam drug-drug interaction study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00961-26
Source records
- crossref · retrieved 2026-11-10T10:02:00.406Z